New hope for recurrent ovarian cancer: targeted drug combo enters human testing

NCT ID NCT06930755

Recruiting now Disease control Sponsor: Nerviano Medical Sciences Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in 24 people whose ovarian cancer has returned after prior treatments. The main goals are to check safety and find the best dose, while also seeing if the combination shrinks tumors. Participants must have a specific type of ovarian cancer and have tried up to 5 prior treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

OSF Saint Francis Medical Center
RECRUITING

Peoria, Illinois, 61637, United States
Penn Medicine - Perelman Center for Advanced Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Washington University School of Medicine in St. Louis
RECRUITING

St Louis, Missouri, 63130, United States

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER